Meeting
2020 ASCO Virtual Scientific Program
The use of plasma proteomic markers to understand the biology of immunotherapy response.
Authors
Arnav Mehta
Dana–Farber Cancer Institute, Boston, MA
Arnav Mehta , Marijana Rucevic , Emmett Sprecher , Lina Hultin Rosenberg , David Lieb , Gyulnara G. Kasumova , Michelle S. Kim , Xue Bai , Dennie T. Frederick , Keith Flaherty , Ryan J. Sullivan , Nir Hacohen , Genevieve Marie Boland
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Biologic Correlates
Citation
J Clin Oncol 38: 2020 (suppl; abstr 10062)
DOI
10.1200/JCO.2020.38.15_suppl.10062
Abstract #
10062
Poster Bd #
411
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Circulating cytokines as predictors of response to immune checkpoint inhibitors (ICIs) in patients (pts) with melanoma (Mel) and non–small cell lung cancer (NSCLC).
First Author: Giulia Pasello
Poster
2020 ASCO Virtual Scientific Program
A proteomic biomarker discovery platform for predicting clinical benefit of immunotherapy in advanced melanoma.
First Author: Yuval Shaked
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Liquid biopsy using plasma proteomic profiling to reveal predictors of immunotherapy response.
First Author: Arnav Mehta
Poster
2018 ASCO Annual Meeting
Serum interleukin 8 (IL-8) may serve as a biomarker of response to immuno-oncology (I-O) therapy.
First Author: Michael Carleton